SCHEMBL4701925

SCHEMBL4701925

Cc1ccc(S(=O)(=O)O/N=C2\CCCc3ncccc32)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.67
CYP2C19 P33261 2/20 0.58
KMT2A Q03164 5/20 0.42
MEN1 O00255 3/20 0.42
MAPT P10636 5/20 0.39
LMNA P02545 4/20 0.39
TDP1 Q9NUW8 4/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HTT P42858 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
HSP90AA1 P07900 1/20 0.39
PKM P14618 1/20 0.39
XBP1 P17861 1/20 0.39
MAPK1 P28482 1/20 0.39
MPI P34949 1/20 0.39
RAB9A P51151 1/20 0.39
PLA2G1B P04054 1/20 0.38
ATG4B Q9Y4P1 1/20 0.38
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4701930 1.00 ALDH1A1 (0.67) ALDH1A1CYP2C19KMT2AMEN1MAPT
SCHEMBL30207746 0.82 ALDH1A1 (0.47) ALDH1A1CYP2C19KMT2AMEN1MAPT
SCHEMBL7015325 0.82 ALDH1A1 (0.61) ALDH1A1CYP2C19KMT2AMEN1MAPT
SCHEMBL7015328 0.82 ALDH1A1 (0.61) ALDH1A1CYP2C19KMT2AMEN1MAPT
SCHEMBL4088854 0.81 ALDH1A1 (0.67) ALDH1A1CYP2C19KMT2AMEN1MAPT
SCHEMBL1104632 0.81 ALDH1A1 (0.67) ALDH1A1CYP2C19KMT2AMEN1MAPT
SCHEMBL15314802 0.81 ALDH1A1 (0.57) ALDH1A1CYP2C19KMT2AMEN1MAPT
SCHEMBL7020831 0.76 ALDH1A1 (0.70) ALDH1A1CYP2C19KMT2AMEN1MAPT
SCHEMBL7018307 0.76 ALDH1A1 (0.70) ALDH1A1CYP2C19KMT2AMEN1MAPT
SCHEMBL7020834 0.76 ALDH1A1 (0.70) ALDH1A1CYP2C19KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3703692-B1 NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-07-23 EP disclosed
US-12275729-B2 Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME LLC (US) 2025-04-15 US disclosed
US-12157726-B2 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof SHANGHAI ZHIMENG BIOPHARMA INC. 2024-12-03 US disclosed
EP-3798220-B1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF SHANGHAI ZHIMENG BIOPHARMA INC (CN) 2023-08-23 EP disclosed
EP-4095138-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF F. Hoffmann-La Roche AG (CH) 2022-11-30 EP disclosed
EP-3555093-B1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2022-09-21 EP disclosed
CN-110072863-B RIP1 kinase inhibitors and methods of use 豪夫迈·罗氏有限公司 2022-08-30 CN disclosed
US-20220227721-A1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF SHANGHAI ZHIMENG BIOPHARMA INC. (CN) 2022-07-21 US disclosed
US-11365181-B2 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof SHANGHAI ZHIMENG BIOPHARMA INC. (CN) 2022-06-21 US disclosed
CN-110511220-B P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine 上海挚盟医药科技有限公司 2022-04-01 CN disclosed
EP-1633348-B1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ELAN PHARM INC (US) 2008-10-08 EP disclosed
US-7432379-B2 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. (US) 2008-10-07 US disclosed
US-7432379-B2 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. (US) 2008-10-07 US disclosed
US-7417152-B2 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2008-08-26 US disclosed
US-7417152-B2 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2008-08-26 US disclosed
US-7417152-B2 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2008-08-26 US disclosed
US-20060281733-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. 2006-12-14 US disclosed
EP-1633348-A1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES Elan Pharmaceuticals, Inc. (US) 2006-03-15 EP disclosed
US-20050020659-A1 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. 2005-01-27 US disclosed
WO-2004098589-A1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ELAN PHARMACEUTICALS, INC. (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157726-B2 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof KCNJ2, KCNN2, KCNH2 ALDH1A1 1733/4885CYP2C19 847/4885KMT2A 671/4885
US-20050020659-A1 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists BDKRB1, BDKRB2, BRS3 ALDH1A1 3054/4885CYP2C19 601/4885KMT2A 3940/4885
US-20220227721-A1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF KCNJ2, KCNN2, KCNH2 ALDH1A1 1733/4885CYP2C19 847/4885KMT2A 671/4885
US-11365181-B2 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof KCNJ2, KCNN2, KCNH2 ALDH1A1 1705/4885CYP2C19 825/4885KMT2A 660/4885
US-12275729-B2 Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, INMT ALDH1A1 730/4885CYP2C19 1486/4885KMT2A 538/4885
US-20060281733-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases BDKRB1, BDKRB2, CNR1 ALDH1A1 2017/4885CYP2C19 418/4885KMT2A 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.